Global S&T Development Trend Analysis Platform of Resources and Environment
Government further boosts chances of UK receiving COVID-19 vaccine | |
admin | |
2020-07-29 | |
发布年 | 2020 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 ; 资源环境 |
正文(英文) |
Press release
Government further boosts chances of UK receiving COVID-19 vaccineDeal announced which will secure early access to a promising new coronavirus vaccine, enhancing the UK’s growing portfolio of vaccine candidates. ![]()
A deal to secure early access to a promising new coronavirus vaccine has been announced by the government today (29 July), enhancing the UK’s growing portfolio of vaccine candidates to protect the public and to save lives. The agreement with GSK and Sanofi Pasteur, which combined have the largest vaccine manufacturing capability in the world, will supply the UK with 60 million doses of their COVID-19 vaccine, which is based on existing DNA-based technology used to produce Sanofi’s flu vaccine. If the GSK and Sanofi vaccine candidate is proven effective in human studies, the UK could be able to vaccinate priority groups, such as frontline health and social care workers and those at increased health risk, as soon as summer 2021. Human clinical studies of the vaccine will begin in September followed by a Phase 3 study in December 2020. With today’s announcement, the government has now secured early access to 4 different types of immunisation and a total of 250 million doses, giving the UK the most likely chance of finding a safe and effective vaccine at the quickest speed. Business Secretary Alok Sharma said:
This latest agreement comes as the government confirmed that almost 72,000 people have volunteered to receive information about participating in future vaccine studies following the launch of the NHS COVID-19 vaccine research registry last week. Only large-scale clinical studies can give scientists and regulators the assurances they need that vaccines secured are safe and effective for use. That is why the government is urging the British public to back the national effort to speed up vaccine research by signing up to www.nhs.uk/coronavirus to receive information about becoming a volunteer for clinical studies. The aim is to get 500,000 people signed up by October. Kate Bingham, Chair of the government’s Vaccines Taskforce, said:
Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur commented:
Roger Connor, President of GSK Vaccines added:
Earlier this month, the government announced it had secured 90 million COVID-19 vaccine doses thanks to partnerships with the BioNTech / Pfizer alliance and Valneva. A deal has also been agreed to secure access to treatments containing COVID-19 neutralising antibodies from AstraZeneca, to protect those who cannot receive vaccines such as cancer and immunocompromised patients. This is in addition to an existing global licensing agreement signed with AstraZeneca and the University of Oxford to research, develop and manufacture a COVID-19 vaccine for the UK public. AstraZeneca will work to produce 100 million doses for the UK in total. Notes to editorsWhen coronavirus invades the body, the immune system fights back in multiple ways including by producing antibodies to neutralize the virus. These antibodies bind to the spike protein on the surface of the coronavirus and prevent them from entering the cells. GSK and Sanofi’s vaccine includes the coronavirus spike protein and the immune boosting adjuvant to trigger a strong and long-lasting immune response (including the production of neutralizing antibodies) against COVID-19 especially in the elderly who are likely to be a priority population for early COVID-19 vaccination. The 4 different vaccine classes that the government has secured to date for the UK are:
In addition the UK has secured rights to AstraZeneca’s antibody treatment to neutralize the virus which can be used both as a short term prophylactic for those people who cannot receive vaccines (for example cancer and immunosuppressed patients) and front line workers exposed to the virus, as well as a treatment for infected patients. Volunteering for COVID-19 vaccine clinical trialsA new NHS service has been launched to enable people across the UK to sign up for information on COVID-19 vaccine trials. The NHS Covid-19 vaccine research registry, developed in partnership with NHS Digital, will help large numbers of people to be recruited into trials over the coming months - potentially meaning an effective vaccine for coronavirus can be found as soon as possible. The service was commissioned as part of the UK government’s Vaccine Taskforce in conjunction with the National Institute for Health Research (NIHR) and the Northern Ireland, Scottish and Welsh governments. Anyone living in the UK can sign up online to take part in the trials through the NHS, giving permission for researchers to contact you if they think you’re a good fit. Once you sign up, you can withdraw at any time and request that your details be removed from the COVID-19 vaccine research registry. The process takes about 5 minutes to complete. Find out more: www.nhs.uk/coronavirus Vaccine priority groups: interim adviceInterim advice from the Joint Committee on Vaccination and Immunisation (JCVI) on the groups that should be prioritised for vaccination, if and when a vaccine is available. The committee advises priority vaccination of the following groups:
There is ongoing work within the UK to refine the identification of persons at risk of serious disease and mortality from COVID-19 infection. As well as age and underlying co-morbid conditions, the committee notes that early signals have been identified of other potential risk factors, including deprivation and ethnicity. As more evidence on at-risk groups emerges, this work will inform the review of the composition, and order of priority, of groups for vaccination. More information is available at Priority groups for coronavirus (COVID-19) vaccination advice.
Published 29 July 2020
|
URL | 查看原文 |
来源平台 | Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/285963 |
专题 | 气候变化 资源环境科学 |
推荐引用方式 GB/T 7714 | admin. Government further boosts chances of UK receiving COVID-19 vaccine. 2020. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论